Loading company
$0.360.0%Nov 13 close
Figures through June 30, 2026, from the 10-Q filed August 19, 2026
Past performance
- 1W
- 0.0%
- 1M
- 0.0%
- 3M
- 0.0%
- 6M
- 0.0%
- 1Y
- -87.0%
- 5Y
- -99.3%
$0.360.0%Nov 13 close
Figures through June 30, 2026, from the 10-Q filed August 19, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1M | $1.2M | -18.93% |
| Profit | -$3.1M | -$4.5M | +31.78% |
| Profit per share | -$0.22 | -$1.08 | +79.63% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
ProPhase Labs, Inc. has no earnings call transcript available.
“With Mayo Clinic’s validation and publication in Clinical and Translational Gastroenterology, BE-Smart™ has proven itself as a next-generation molecular triage tool for Barrett’s disease,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ProPhase Labs, Inc.’s Item 2.02 8-K filed November 19, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.